Basit öğe kaydını göster

Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole

dc.contributor.authorGokturk, S.
dc.contributor.authorEmrence, Zeliha
dc.contributor.authorBesisik, F.
dc.contributor.authorSoyer, O. M.
dc.contributor.authorKaymakoglu, S.
dc.contributor.authorAkyuz, F.
dc.contributor.authorEvirgen, S.
dc.contributor.authorOrmeci, A.
dc.contributor.authorBaran, B.
dc.contributor.authorUstek, D.
dc.contributor.authorDemir, K.
dc.contributor.authorKaraca, C.
dc.date.accessioned2021-03-06T07:43:42Z
dc.date.available2021-03-06T07:43:42Z
dc.date.issued2016
dc.identifier.citationOrmeci A., Emrence Z., Baran B., Gokturk S., Soyer O. M. , Evirgen S., Akyuz F., Karaca C., Besisik F., Kaymakoglu S., et al., "Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole", European Review for Medical and Pharmacological Sciences, cilt.20, ss.879-885, 2016
dc.identifier.issn1128-3602
dc.identifier.otherav_dd974e67-9a8b-4f7b-bfa9-28575b7b3124
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/146005
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016996843&origin=inward
dc.description.abstractOBJECTIVE: Cytochrome P450 2C19 (CYP2C19) polymorphisms play an important role in the metabolism of proton pump inhibitors. Rabeprazole is primarily metabolized via non-enzymatic pathways. In this study, we determined whether rabeprazole- and pantoprazole-based eradication treatments were influenced by CYP2C19 polymorphisms.
dc.language.isoeng
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleEffect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole
dc.typeMakale
dc.relation.journalEuropean Review for Medical and Pharmacological Sciences
dc.contributor.departmentKoç Üniversitesi , ,
dc.identifier.volume20
dc.identifier.issue5
dc.identifier.startpage879
dc.identifier.endpage885
dc.contributor.firstauthorID90219


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster